Raymond James Got Gilead Sciences (NASDAQ:GILD) Covered with $93 Target.

June 29, 2018 - By Noel Courtney

Gilead Sciences, Inc. (NASDAQ:GILD) Corporate Logo

Big Money Sentiment increased to 0.88 in Q1 2018. It has change of 0.08, from 2017Q4’s 0.8. The ratio improved due to Gilead Sciences, Inc. positioning: 71 sold and 519 reduced. 114 funds bought holdings and 404 increased holdings. Investors holded 972.68 million in 2017Q4 but now own 976.44 million shares or 0.39% more.

Excalibur reported 13,536 shs stake. Underhill Mngmt Ltd Liability Corporation has invested 7.43% in Gilead Sciences, Inc. (NASDAQ:GILD). Fulton Breakefield Broenniman Ltd Com, a Maryland-based fund reported 82,523 shs. Timber Hill Limited Liability has invested 0.52% in Gilead Sciences, Inc. (NASDAQ:GILD). First Foundation Advsrs owns 64,942 shs or 0.27% of their US capital. Schwab Charles Inv Management Incorporated has 5.22M shs. Penobscot Inc accumulated 0.13% or 7,050 shs. Long Road Counsel Limited Liability accumulated 25,000 shs. Duff And Phelps Invest holds 13,960 shs. Aimz Limited Liability owns 38,438 shs. Ferguson Wellman Capital Mngmt, a Oregon-based fund reported 35,455 shs. Burney holds 0.23% or 48,727 shs. Smithfield holds 4,330 shs or 0.04% of its capital. Moreover, Rmb Capital Mngmt Ltd Llc has 0.11% invested in Gilead Sciences, Inc. (NASDAQ:GILD) for 54,604 shs. Meyer Handelman has invested 1.11% in Gilead Sciences, Inc. (NASDAQ:GILD).

Gilead Sciences, Inc. registered $48.21 million net activity with 0 buys and 23 sales since January 2, 2018. 50,000 shs were sold by MARTIN JOHN C, worth $3.68M. Another trade for 5,000 shs valued at $401,566 was made by Washington Robin L on Wednesday, February 21. Meyers James R also sold $8.02 million worth of Gilead Sciences, Inc. (NASDAQ:GILD) on Tuesday, January 16. Alton Gregg H sold $1.18M worth of stock or 14,435 shs. On Friday, February 9 WILSON GAYLE E also sold $4.68M worth of Gilead Sciences, Inc. (NASDAQ:GILD).

What Price Target Has Raymond James Given Gilead Sciences (NASDAQ:GILD)

Today an analyst note was made public, in which Raymond James analyst started coverage of Gilead Sciences (NASDAQ:GILD) with “Strong Buy” rating. The Stock analysts give $93 target which would indicate upside potential of 30.47 % on GILD’s shares.

Gilead Sciences, Inc. (NASDAQ:GILD) Ratings Coverage

In total 16 analysts cover Gilead Sciences (NASDAQ:GILD). “Buy” rating has 11, “Sell” are 0, while 5 are “Hold”. (NASDAQ:GILD) has 69% bullish analysts. 24 are the (NASDAQ:GILD)’s ratings reports on Jun 29, 2018 according to StockzIntelligence Inc. On Wednesday, February 7 the firm has “Equal-Weight” rating given by Morgan Stanley. On Thursday, May 31 the rating was reinitiated by PiperJaffray with “Overweight”. On Tuesday, January 30 the rating was upgraded by Citigroup to “Buy”. On Monday, February 5 the company was maintained by Mizuho. The company rating was maintained by Leerink Swann on Wednesday, May 2. On Wednesday, February 7 Bank of America maintained Gilead Sciences, Inc. (NASDAQ:GILD) with “Neutral” rating. On Wednesday, February 7 BMO Capital Markets maintained the shares of GILD in report with “Hold” rating. On Wednesday, May 2 Morgan Stanley maintained the shares of GILD in report with “Equal-Weight” rating. The stock rating was maintained by Leerink Swann with “Hold” on Thursday, February 22. The stock rating was maintained by Leerink Swann with “Market Perform” on Wednesday, February 7.

Ticker’s shares touched $71.28 during the last trading session after 1.35% change.Gilead Sciences, Inc. has volume of 1.76M shares. Since June 29, 2017 GILD has risen 4.37% and is uptrending. The stock underperformed the S&P500 by 8.20%.

On July, 25. Investors wait Gilead Sciences, Inc. (NASDAQ:GILD) to announce its quarterly earnings, Faxor reports. Analysts predict $1.42 EPS, which is $1.09 down or 43.43 % from 2017’s $2.51 EPS. If $1.42 is reported, GILD’s profit will reach $1.85 billion for 12.55 P/E. After $1.37 EPS was published last quarter, analysts now see EPS growth of 3.65 % for Gilead Sciences, Inc..

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally.The company has $92.68 billion market cap. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.The P/E ratio is 27.11. It also provides Yescarta, a chimeric antigen receptor T cell therapy for adult patients with relapsed or refractory large B-cell lymphoma; Zydelig, a PI3K delta inhibitor for certain blood cancers; Letairis, an oral formulation of an endothelin receptor antagonist for pulmonary arterial hypertension; Ranexa, a tablet to treat chronic angina; and Lexiscan, an injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging.

For more Gilead Sciences, Inc. (NASDAQ:GILD) news published recently go to: Seekingalpha.com, Seekingalpha.com, Investorplace.com, Nasdaq.com or Seekingalpha.com. The titles are as follows: “Gilead: Growth Pick For Your Portfolio” published on June 15, 2018, “Gilead Sciences Is Too Cheap To Ignore – Cramer’s Lightning Round (6/22/18)” on June 25, 2018, “7 Best Dividend Stocks With Loads of Cash in the Bank” with a publish date: June 28, 2018, “Has the Gilead Sciences Buy Argument Collapsed?” and the last “Gilead Oncology CAR T-Cell Therapies Outlook Compelling” with publication date: June 18, 2018.

Gilead Sciences, Inc. (NASDAQ:GILD) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.